Skip to main content
. 2017 Jan 31;6(4):e1285992. doi: 10.1080/2162402X.2017.1285992

Figure 5.

Figure 5.

Impact of CD8+ T cell depletion on the therapeutic efficacy of MeVac FmIL-12. C57BL/6J mice were depleted of CD8+ T cells (Minus CD8+) by intraperitoneal antibody injections or left undepleted (mock, undepleted). MC38cea tumor cells were implanted subcutaneously and established tumors were treated with intratumoral (i.t.) injections of 1 × 106 cell infectious units of MeVac encoding FmIL-12 (Minus CD8+, undepleted) in 100 µL on four consecutive days. Mock treated animals received i.t. OptiMEM injections. Kaplan–Meier survival analysis is shown.